BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 32697050)

  • 21. The location of KIT and PDGFRA gene mutations in gastrointestinal stromal tumours is site and phenotype associated.
    Penzel R; Aulmann S; Moock M; Schwarzbach M; Rieker RJ; Mechtersheimer G
    J Clin Pathol; 2005 Jun; 58(6):634-9. PubMed ID: 15917417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential expression of KIT/PDGFRA mutant isoforms in epithelioid and mixed variants of gastrointestinal stromal tumors depends predominantly on the tumor site.
    Wasag B; Debiec-Rychter M; Pauwels P; Stul M; Vranckx H; Oosterom AV; Hagemeijer A; Sciot R
    Mod Pathol; 2004 Aug; 17(8):889-94. PubMed ID: 15154005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spectrum and prognostication of KIT and PDGFRA mutation in gastrointestinal stromal tumors.
    Tzen CY; Wang MN; Mau BL
    Eur J Surg Oncol; 2008 May; 34(5):563-8. PubMed ID: 17532173
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Therapeutic targets in gastrointestinal stromal tumors].
    Wardelmann E; Schildhaus HU; Merkelbach-Bruse S; Büttner R
    Verh Dtsch Ges Pathol; 2006; 90():73-9. PubMed ID: 17867582
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases.
    Lasota J; Corless CL; Heinrich MC; Debiec-Rychter M; Sciot R; Wardelmann E; Merkelbach-Bruse S; Schildhaus HU; Steigen SE; Stachura J; Wozniak A; Antonescu C; Daum O; Martin J; Del Muro JG; Miettinen M
    Mod Pathol; 2008 Apr; 21(4):476-84. PubMed ID: 18246046
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutations in gastrointestinal stromal tumors--a population-based study from Northern Norway.
    Steigen SE; Eide TJ; Wasag B; Lasota J; Miettinen M
    APMIS; 2007 Apr; 115(4):289-98. PubMed ID: 17504295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors.
    Singer S; Rubin BP; Lux ML; Chen CJ; Demetri GD; Fletcher CD; Fletcher JA
    J Clin Oncol; 2002 Sep; 20(18):3898-905. PubMed ID: 12228211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours.
    Agaimy A; Terracciano LM; Dirnhofer S; Tornillo L; Foerster A; Hartmann A; Bihl MP
    J Clin Pathol; 2009 Jul; 62(7):613-6. PubMed ID: 19561230
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gastrointestinal stromal tumors presenting as omental masses--a clinicopathologic analysis of 95 cases.
    Miettinen M; Sobin LH; Lasota J
    Am J Surg Pathol; 2009 Sep; 33(9):1267-75. PubMed ID: 19440146
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes.
    Burger H; den Bakker MA; Kros JM; van Tol H; de Bruin AM; Oosterhuis W; van den Ingh HF; van der Harst E; de Schipper HP; Wiemer EA; Nooter K
    Cancer Biol Ther; 2005 Nov; 4(11):1270-4. PubMed ID: 16294026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [c-Kit and PDGFRA mutations and clinico-morphological features of gastrointestinal stromal tumors].
    Beliakov IS; Anurova OA; Snigur PV; Tsyganova IV; Sel'chuk VIu; Mazurenko NN
    Vopr Onkol; 2007; 53(6):677-81. PubMed ID: 18416137
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation between mutational status and survival and second cancer risk assessment in patients with gastrointestinal stromal tumors: a population-based study.
    Rubió-Casadevall J; Borràs JL; Carmona-García MC; Ameijide A; Gonzalez-Vidal A; Ortiz MR; Bosch R; Riu F; Parada D; Martí E; Miró J; Sirvent JJ; Galceran J; Marcos-Gragera R
    World J Surg Oncol; 2015 Feb; 13():47. PubMed ID: 25885906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutation analysis of gastrointestinal stromal tumors: increasing significance for risk assessment and effective targeted therapy.
    Wardelmann E; Büttner R; Merkelbach-Bruse S; Schildhaus HU
    Virchows Arch; 2007 Oct; 451(4):743-9. PubMed ID: 17701051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS).
    Martín J; Poveda A; Llombart-Bosch A; Ramos R; López-Guerrero JA; García del Muro J; Maurel J; Calabuig S; Gutierrez A; González de Sande JL; Martínez J; De Juan A; Laínez N; Losa F; Alija V; Escudero P; Casado A; García P; Blanco R; Buesa JM;
    J Clin Oncol; 2005 Sep; 23(25):6190-8. PubMed ID: 16135486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors.
    Lasota J; vel Dobosz AJ; Wasag B; Wozniak A; Kraszewska E; Michej W; Ptaszynski K; Rutkowski P; Sarlomo-Rikala M; Steigen SE; Schneider-Stock R; Stachura J; Chosia M; Ogun G; Ruka W; Siedlecki JA; Miettinen M
    Lab Invest; 2007 Oct; 87(10):1029-41. PubMed ID: 17632543
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic and pathologic characteristics of gastrointestinal stromal tumors in extragastric lesions.
    Cho S; Kitadai Y; Yoshida S; Tanaka S; Yoshihara M; Yoshida K; Chayama K
    Int J Mol Med; 2006 Dec; 18(6):1067-71. PubMed ID: 17089009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of mutation and expression of c-kit and PDGFR-alpha gene in gastrointestinal stromal tumor.
    Zheng S; Chen LR; Wang HJ; Chen SZ
    Hepatogastroenterology; 2007 Dec; 54(80):2285-90. PubMed ID: 18265649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low frequency of MAP kinase pathway alterations in KIT and PDGFRA wild-type GISTs.
    Martinho O; Gouveia A; Viana-Pereira M; Silva P; Pimenta A; Reis RM; Lopes JM
    Histopathology; 2009 Jul; 55(1):53-62. PubMed ID: 19614767
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutations in exon 11 of the c-kit gene in a myogenic tumor and a neurogenic tumor as well as in gastrointestinal stromal tumors. Utility of c-kit mutation as a prognostic biomarker for gastrointestinal mesenchymal tumor.
    Yasuoka R; Sakakura C; Shimomura K; Fujita Y; Nakanishi M; Aragane H; Hagiwara A; Bamba M; Abe T; Yamagishi H
    Dig Surg; 2003; 20(3):183-91. PubMed ID: 12759497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of patients with advanced gastrointestinal stromal tumor of small bowel: implications of imatinib mesylate.
    Yeh CN; Chen TW; Wu TJ; Hsueh S; Jan YY
    World J Gastroenterol; 2006 Jun; 12(23):3760-5. PubMed ID: 16773696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.